Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Credit Suisse Maintains Neutral on CRISPR Therapeutics, Lowers Price Target to $78

Credit Suisse analyst Richard Law maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral and lowers the price target from $90 to $78.
byBenzinga Newsdesk
November 2, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Credit Suisse analyst Richard Law maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral and lowers the price target from $90 to $78.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts